Imunon, Inc. Files S-1/A Amendment
Ticker: IMNN · Form: S-1/A · Filed: Sep 20, 2024 · CIK: 749647
Sentiment: neutral
Topics: sec-filing, registration, amendment
Related Tickers: IMNN
TL;DR
Imunon (IMNN) filed an S-1/A, looks like they're raising capital or making regulatory changes.
AI Summary
Imunon, Inc. filed an S-1/A amendment on September 20, 2024, for its registration statement. The company, formerly known as Celsion Corp, is incorporated in Delaware and headquartered in Lawrenceville, NJ. This filing relates to the registration of securities under the Securities Act of 1933.
Why It Matters
This filing indicates Imunon, Inc. is actively pursuing a securities offering or other regulatory actions related to its stock, which could impact its capital structure and future operations.
Risk Assessment
Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which carry inherent market risks.
Key Numbers
- 333-281834 — SEC File Number (Identifies this specific registration filing)
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- Celsion Corp (company) — Former company name
- September 20, 2024 (date) — Filing date
- 333-281834 (registration_number) — SEC File Number
FAQ
What is the primary purpose of this S-1/A filing for Imunon, Inc.?
The S-1/A filing is an amendment to a registration statement under the Securities Act of 1933, indicating potential actions related to the registration of securities.
When was this amendment filed with the SEC?
This amendment was filed on September 20, 2024.
What was Imunon, Inc. formerly known as?
Imunon, Inc. was formerly known as Celsion Corp.
Where is Imunon, Inc. incorporated and what is its principal business address?
Imunon, Inc. is incorporated in Delaware and its principal business address is 997 Lenox Drive, Suite 100, Lawrenceville, New Jersey 08648.
What is the SEC Act associated with this filing?
The SEC Act associated with this filing is the 1933 Act.
Filing Stats: 4,633 words · 19 min read · ~15 pages · Grade level 13.8 · Accepted 2024-09-20 16:05:48
Key Financial Figures
- $0.01 — o 5,000,000 shares of the common stock, $0.01 par value per share, of Imunon, Inc., o
- $1.07 — rted sale price of our common stock was $1.07 per share. Investing in our securitie
- $2.00 — rrants, which have an exercise price of $2.00 and will expire five and one half years
- $10.0 million — we would receive aggregate proceeds of $10.0 million. If we receive any cash proceeds, we cu
- $2.19 — ng a weighted average exercise price of $2.19 per share; 789,297 shares of common s
- $2.87 — eighted average grant day fair value of $2.87 per share; 160,060 shares of common s
- $18.86 — ng a weighted average exercise price of $18.86 per share; and 779,020 shares of comm
Filing Documents
- forms-1a.htm (S-1/A) — 299KB
- ex23-1.htm (EX-23.1) — 3KB
- 0001493152-24-037591.txt ( ) — 544KB
- imnn-20240912.xsd (EX-101.SCH) — 3KB
- imnn-20240912_def.xml (EX-101.DEF) — 26KB
- imnn-20240912_lab.xml (EX-101.LAB) — 36KB
- imnn-20240912_pre.xml (EX-101.PRE) — 25KB
- forms-1a_htm.xml (XML) — 5KB
RISK FACTORS
RISK FACTORS 4 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 5
USE OF PROCEEDS
USE OF PROCEEDS 6 DIVIDEND POLICY 7 MARKET FOR OUR COMMON STOCK 8 SELLING STOCKHOLDERS 9 PLAN OF DISTRIBUTION 11 LEGAL MATTERS 12 EXPERTS 12 WHERE YOU CAN FIND MORE INFORMATION 12 INCORPORATION OF DOCUMENTS BY REFERENCE 12 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, under which the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings . This prospectus contains information that you should consider when making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with information that is different from or in addition to the information contained in this prospectus. Accordingly, neither we nor any Selling Stockholder takes any responsibility for, or can provide any assurance as to the reliability of, any information that others may give. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than where offers and sales of these securities are permitted or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus is accurate only as of the date of this prospectus and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, or any sale of our common stock . Our business, financial condition, results of operations and prospects may have changed materially since those dates. Unless the context otherwise requires, "Imunon," "IMNN," "the Company," "we," "us